Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Increased scale of manufacturing, efficient cold-chain logistics, and increasing investments by biopharma stakeholders reduces unit cost and increases geographic presence, especially into previously underpenetrated emerging markets, thus, solidifying clinical partnerships and distribution networks
Additional code used for these analyses is available at References Hruby, A
The Trump administrations recent Most Favored Nation (MFN) pricing deal, announced in November 2025, represented the first major effort to close that gap, anchoring widely discussed consumer prices around $350 per month for many injectable GLP-1 through manufacturer self-pay programs
In total, 1,797 patients (56.5%) had established CV disease without CKD, 354 patients (11.1%) had CKD only, and 544 patients (17.1%) had both CV disease and CKD
63 Albiglutide was approved for marketing in the European Union in March 2014 and in the United States in April 2014
US$ 26.49
US$ 27.04
US$ 28.49
US$ 26.92
